Claims
- 1. A method of treating or preventing the effects of radiation in a mammal exposed to radiation, said method comprising administering to said mammal a therapeutically effective amount of an isoflavone.
- 2. The method of claim 1 wherein said radiation is selected from the group consisting of an acute lethal dose of ionizing radiation, an acute sub-lethal dose of ionizing radiation, a chronic low-dose of ionizing radiation, an acute lethal dose of non-ionizing radiation, an acute sub-lethal dose of non-ionizing radiation, and a chronic low-dose of non-ionizing radiation.
- 3. The method of claim 2 wherein said radiation is selected from the group consisting of diagnostic X-rays, radiation therapy in cancer treatment, CAT-scans, mammograms, radionuclide scans, interventional radiological procedures under CT or fluoroscopy guidance, tissue-incorporated radionuclides from ingestion of contaminated food or water, and uncontrolled exposure to ionizing radiation from nuclear weapons, radioactive spills, and/or cosmic radiation.
- 4. The method of claim 1 wherein said isoflavone is selected from the group consisting of genistein, genistin, daidzein, daidzin, glycitein, glycitin, biochannin A, formononetin, O-desmethylangolensin, and equol, their glucosides and derivatives, and mixtures thereof.
- 5. The method of claim 1 wherein said isoflavone is administered orally, subcutaneously, intramuscularly, intravenously, transdermally, intranasally, or rectally.
- 6. The method of claim 5 where said isoflavone is administered orally in the form of a capsule, a tablet, an inhaler, a troche, or a food supplement in the form of a food or beverage.
- 7. The method of claim 1 wherein said isoflavone is administered chronically.
- 8. The method of claim 1 wherein said isoflavone is administered within 2 weeks prior to exposure to radiation, during radiation exposure, and/or within 2 weeks following radiation exposure.
- 9. The method of claim 8 wherein said isoflavone is administered within 4 days prior to radiation exposure, during radiation exposure, and/or within 4 days following radiation exposure.
- 10. A method of treating or preventing damage to living cells, tissues and organs caused by exposure to radiation, said method comprising administering to a therapeutically effective amount of an isoflavone.
- 11. The method of claim 10 wherein said radiation is selected from the group consisting of an acute lethal dose of ionizing radiation, an acute sub-lethal dose of ionizing radiation, a chronic low-dose of ionizing radiation, an acute lethal dose of non-ionizing radiation, an acute sub-lethal dose of non-ionizing radiation, and a chronic low-dose of non-ionizing radiation.
- 12. The method of claim 11 wherein said radiation is selected from the group consisting of diagnostic X-rays, radiation therapy in cancer treatment CAT-scans, mammograms, radionuclide scans, interventional radiological procedures under CT or fluoroscopy guidance, tissue-incorporated radionuclides from ingestion of contaminated food or water, and uncontrolled exposure to ionizing radiation from nuclear weapons, radioactive spills, and/or cosmic radiation.
- 13. The method of claim 10 wherein said isoflavone is selected from the group consisting of genistein, genistin, daidzein, daidzin, glycitein, glycitin, biochannin A, formononetin, O-desmethylangolensin, and equol, their glucosides and derivatives, and mixtures thereof.
- 14. The method of claim 10 wherein said isoflavone is administered chronically.
- 15. The method of claim 10 wherein said isoflavone is administered within 2 weeks prior to exposure to radiation, during radiation exposure, and/or within 2 weeks following radiation exposure.
- 16. The method of claim 15 wherein said isoflavone is administered within 4 days prior to radiation exposure, during radiation exposure, and/or within 4 days following radiation exposure.
- 17. A method of protecting personnel exposed to radioactive substances, said method comprising administering to said personnel a therapeutically effective amount of an isoflavone.
- 18. The method of claim 17 wherein said radiation is selected from the group consisting of an acute lethal dose of ionizing radiation, an acute sub-lethal dose of ionizing radiation, a chronic low-dose of ionizing radiation, an acute lethal dose of non-ionizing radiation, an acute sub-lethal dose of non-ionizing radiation, and a chronic low-dose of non-ionizing radiation.
- 19. The method of claim 18 wherein said radiation is selected from the group consisting of diagnostic X-rays, radiation therapy in cancer treatment, CAT-scans, mammograms, radionuclide scans, interventional radiological procedures under CT or fluoroscopy guidance, tissue-incorporated radionuclides from ingestion of contaminated food or water, and uncontrolled exposure to ionizing radiation from nuclear weapons, radioactive spills, and/or cosmic radiation.
- 20. The method of claim 17 wherein said isoflavone is selected from the group consisting of genistein, genistin, daidzein, daidzin, glycitein, glycitin, biochannin A, formononetin, O-desmethylangolensin, and equol, their glucosides and derivatives, and mixtures thereof.
- 21. The method of claim 17 wherein said isoflavone is administered orally, subcutaneously, intramuscularly, intravenously, transdermally, intranasally, or rectally.
- 22. The method of claim 21 where said isoflavone is administered orally in the form of a capsule, a tablet, an inhaler, a troche, or a food supplement in the form of a food or beverage.
- 23. The method of claim 17 wherein said isoflavone is administered chronically.
- 24. The method of claim 17 wherein said isoflavone is administered within 2 weeks prior to exposure to radiation, during radiation exposure, and/or within 2 weeks following radiation exposure.
- 25. The method of claim 24 wherein said isoflavone is administered within 4 days prior to radiation exposure, during radiation exposure, and/or within 4 days following radiation exposure.
- 26. A method for increasing survivability of mammals from a lethal dose of radiation, said method comprising administering to said mammal before, during and/or after said lethal dose of radiation a therapeutically effective amount of a compound of the formula:
- 27. The method for increasing survivability of mammals from a lethal dose of radiation as defined in claim 26 wherein said compound is genistein.
- 28. A method for increasing survivability of mammals from a lethal dose of radiation as defined in claim 12 wherein said compound is administered to said mammal during the time period of approximately 4 days prior to radiation exposure to approximately 4 days subsequent to said lethal dose of irradiation.
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims benefit under 35 USC §119(e) of U.S. Provisional Application Serial No. 60/211,375, filed Jun. 14, 2000.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60211375 |
Jun 2000 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
PCT/US01/18772 |
Jun 2001 |
US |
Child |
09916257 |
Jul 2001 |
US |